CS Diagnostics SEC Filings

CS Diagnostics Corp. reports 2025 results showing how early-stage and financially constrained the business remains. Revenue was $204,000, all from a related-party Affiliate Revenue Agreement, and net income was $71,219, meaning earnings came from affiliate support rather than product sales.

Total assets were about $499.5 million, almost entirely a single cancer-treatment intellectual property asset valued at $499.4 million, while cash was only $6,813 and liabilities were $15,262. The company has not yet generated product-based revenue and depends on affiliates, equity raises, and a share subscription facility to fund operations.

Management discloses substantial doubt about the company’s ability to continue as a going concern, even though it believes planned financings and affiliate support can cover the next 12 months. The auditor issued a going concern emphasis and highlighted the massive HYDROGEL intangible asset as a critical audit matter. The company also reports a material weakness in internal control over financial reporting related to its period-end close process, which it is working to remediate.

CS Diagnostics Corp. notifies the SEC it cannot file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 within the prescribed time and is requesting the 15‑calendar‑day extension under Rule 12b-25. The company states it needs additional time to complete financial statements and for its independent auditor to finish audit procedures. The registrant currently expects to file within the permitted 15‑day extension period and anticipates its results for the fiscal year ended December 31, 2025 will show a 25% increase in revenue versus the prior year.

CS Diagnostics Corp. filed Amendment No. 3 to a Form 10 registration under Section 12(g) to register its Common Stock, par value $0.00001 per share. The amendment incorporates an accompanying Information Statement (Exhibit 99.1) by reference and lists governance, license, distribution, asset purchase, valuation and product exhibits.

The filing cross-references business, risk factors, capitalization, security ownership, executive compensation, related-party transactions, legal proceedings and financial statements to the incorporated information statement.

CS Diagnostics Pharma GmbH filed an initial ownership report for CS Diagnostics Corp. (CSDX). The filing shows beneficial ownership of 104,507,800 shares of common stock held directly as of December 31, 2025, establishing the entity as a more than 10% shareholder.

CS Interpharm General Trading Co. LLC filed an initial ownership report showing a large stake in CS Diagnostics Corp. (CSDX). The filing reports beneficial ownership of 42,560,096 shares of CS Diagnostics common stock held directly as of December 31, 2025. No derivative securities such as options or warrants are listed in the report.

CS Interpharm LLC filed an initial ownership report for CS Diagnostics Corp., indicating beneficial ownership of 49,362,500 shares of Common Stock as of 12/31/2025. The filing classifies CS Interpharm LLC as a 10% owner with direct ownership of these shares.

CS Diagnostics Corp. filed Amendment No. 2 to its Form 10 to register its common stock under Section 12(g) of the Exchange Act. The filing covers common stock with a par value of $0.00001 per share and classifies the company as a smaller reporting company. Instead of repeating full disclosure, it incorporates by reference an information statement that includes sections on business, risk factors, management’s discussion and analysis, capitalization, security ownership, and executive compensation, along with audited financial statements. The exhibits list key corporate documents such as amended bylaws, an asset purchase agreement with CS Group, several license and distribution agreements related to MEDUSA products, and hydrogel-related valuation and study materials, providing investors with detailed background on the company’s operations and intellectual property arrangements.

CS Diagnostics Corp. reported its Q3 2025 results. For the nine months ended September 30, 2025, revenue was $94,200 versus $106,381 a year ago, while net income improved to $32,081 from $13,448, mainly on lower operating expenses. In Q3, the company posted a small net loss of $182 on revenue of $23,050.

Total assets were $499,431,013, driven by $499.4 million of intangible assets. Cash was $13 as of September 30, 2025, with accounts payable of $1,609. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing limited liquidity and the need for additional financing.

The capital structure included 137,340,200 common shares outstanding, 10 shares of Series A preferred, 19,992,575 of Series B preferred, and 4,000,000 of Series C preferred. The company noted pending civil actions and stated internal controls over disclosure were effective as of September 30, 2025.

CS Diagnostics Corp. (CSDX) completed a capital conversion, exchanging all outstanding Series B Preferred Stock held by affiliates into an aggregate 112,652,000 Common Shares on October 30, 2025.

The exchange was conducted under Securities Act exemptions Section 3(a)(9) (existing holders; no commission paid) and, alternatively, Section 4(a)(2). The company states the move aligns capital structures ahead of consolidated financial reporting for the fiscal year ending December 31, 2025.

Following the conversion, the affiliates now hold Common Shares and remain subject to Rule 144 resale limitations, including filing, volume, manner-of-sale, and current-public-information requirements.